Company intelligence / Profile preview

Plexāā

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Plexāā has demonstrated, via proof-of-concept clinical trials, that its fully wearable BLOOM⁴³ device can reduce wound healing complications in breast cancer surgery by using intermittent thermal preconditioning to release heat-shock proteins, enhancing blood flow and surgical outcomes. Substantial improvements in patient experience and readiness have been observed. Commercial launch in the U.S. is imminent, and the device is being trialed at Stanford University Hospital.

Therapeutic areas: Women's HealthOncologyOther
Modalities: DeviceDigital health
Industry: Therapeutic Medical Devices

Partnerships

Panasonic Manufacturing UK (contract manufacturing)Stanford University Hospital (clinical trial site)Various clinicians, patients, and partners for global expansion

Beyond the preview

Go deeper on Plexāā.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plexāā.

Explore the full profile